Department of Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine
Peter Zage, M.D., Ph.D.
1102 Bates Street, Suite 1220.o0
Houston, TX 77030
Dr. Peter Zage is a member of the Solid Tumor Program, Neuroblastoma Program, and the Developmental Therapeutics Program. He is interested in the efficacy of novel therapies for children with neuroblastoma, retinoblastoma, and other childhood solid tumors.
M.D., Columbia University College of Physicians and Surgeons
Ph.D., Columbia University Graduate School of Arts & Sciences
Residency, University of Chicago Children’s Hospital
Fellowship, Children’s Memorial Hospital
American Board of Pediatrics
American Board of Pediatrics – Hematology/Oncology
Fellow, American Academy of Pediatrics (AAP)
Member, American Society for Pediatric Hematology/Oncology (ASPHO)
Member, American Society of Clinical Oncology (ASCO)
Member, American Association for Cancer Research (AACR)
Member, Children’s Oncology Group (COG)
Member, Texas Society of Medical Oncology (TSMO)
Member, Harris County Medical Society (HCMS)
Member, Texas Pediatric Society (TPS)
Efficacy of novel therapies for children with neuroblastoma, retinoblastoma, and other childhood solid tumors
Novel therapies are desperately needed for children with many types of cancers to improve outcomes and reduce the incidence and severity of long-term complications. In our laboratory, we are interested in evaluating the efficacy of novel therapies for children with neuroblastoma, retinoblastoma, and other childhood solid tumors and in understanding the critical genetic and molecular events that could be used as targets for new treatments.
We have developed a research program using the latest technologies that has identified several effective agents and new combinations, and we are currently evaluating the efficacy of a variety of tyrosine kinase inhibitors and other novel agents in our model systems. We are developing a comprehensive program for the treatment of children with recurrent or refractory neuroblastoma, including chemotherapy, novel biologically targeted agents, and immunotherapy, and we are collaborating with other institutions in the development of other novel approaches to treatments for all children with cancer.
Peter Zage, M.D., Ph.D.
Kathleen Scorsone, Ph.D.
Linna Zhang, M.D.
Sarah Woodfield, Ph.D.